The US FDA has approved an injectable hyaluronic acid dermal filler for improving the appearance of neck lines in adults older than 21 years, according to the manufacturer.

The product, which contains 0.3% lidocaine, is the first approved specifically to improve the appearance of horizontal neck wrinkles, the company, Allergan Aesthetics, said in a press release announcing the approval. In addition to aging and sun damage, these lines are a result of weight loss and looking down at phones and tablets for long periods, referred to as “tech-neck,” the release said.

The product, marketed as SKINVIVE by JUVÉDERM, was approved by the FDA in 2023 to improve the appearance of facial smoothness in the cheeks for adults older than 21 years. Results of treating horizontal neck lines last for 6 months with optimal treatment, according to the press release.

Approval was supported by data from an unpublished, randomized, multicenter study in which approximately 75% of 105 adults older than 21 years who received treatment in the neck experienced clinically significant improvements, defined as an increase of at least one point on the five-grade Allergan Transverse Neck Lines Scale at 1 month, according to the press release. Some patients may require an optional touch-up treatment 1 month after initial treatment to achieve the desired aesthetic outcome, according to the company.

SKINVIVE is contraindicated for anyone with a history of anaphylactic reactions, multiple severe allergies, or allergies to lidocaine or the gram-positive bacterial proteins in the product, as well as anyone with previous allergic reactions to hyaluronic acid fillers, according to the company.

Adverse events reported by participants in the clinical trial included redness, bruising, tenderness, lumps or bumps, swelling, firmness, pain, discoloration, and itching at the injection sites, based on electronic diary entries, according to the press release. Most were mild and did not require treatment, and most resolved within 2 weeks. Severe adverse events occurred in less than 5% of participants. Notably, the safety and effectiveness of the product have not yet been studied in people with darker skin tones, according to the company.

The company expects the product to be commercially available for the new indication later in 2026. The FDA is requiring that the company provide a training program for providers, which must be completed before they can purchase and administer the product.